Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > pSivida to Present at Cowen and Company Health Care Conference - Boston

Abstract:
pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that the Company's Managing Director, Dr Paul Ashton is making a company presentation in Boston today at the Cowen & Company 28th Annual Health Care Conference.

pSivida to Present at Cowen and Company Health Care Conference - Boston

Boston, MA and PERTH, Australia | Posted on March 18th, 2008

Dr Ashton's presentation will be webcast on the Cowen & Company's website and will also be available on pSivida's website.

www.corporate-ir.net/ireye/confLobby.zhtml?ticker=PSDV&item_id=1779994 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

http://www.psivida.com/News/Presentations.asp

####

About pSivida Limited
pSivida is a global drug delivery company committed to the biomedical sector and the development of drug development of drug delivery products. Retisert® is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the treatment of AIDS-related CMV Retinitis. Bausch & Lomb owns the trademarks Vitrasert® and Retisert®. pSivida has licensed the technologies underlying both of these products to Bausch & Lomb. The technology underlying Medidur™ for diabetic macular edema is licensed to Alimera Sciences and is in Phase III clinical trials. pSivida has a worldwide collaborative research and license agreement with Pfizer Inc. for other ophthalmic applications of the Medidur™ technology (excluding FA).

pSivida owns the rights to develop and commercialize a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon™, which has applications in drug delivery, wound healing, orthopedics, and tissue engineering. The most advanced BioSilicon™ product, BrachySil™ delivers a therapeutic, P32 directly to solid tumors and is presently in Phase II clinical trials for the treatment of pancreatic cancer.

pSivida’s intellectual property portfolio consists of 64 patent families, 113 granted patents, including patents accepted for issuance, and over 280 patent applications. pSivida conducts its operations from Boston in the United States, Malvern in the United Kingdom and Perth in Australia.

pSivida is listed on NASDAQ (PSDV), the Australian Stock Exchange (PSD) and on the Frankfurt Stock Exchange on the XETRA system (PSI). pSivida is a founding member of the NASDAQ Health Care Index and the Merrill Lynch Nanotechnology Index.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking and involve a number of risks and uncertainties. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the forward-looking statements: achievement of milestones and other contingent contractual payment events; failure to prove efficacy for BrachySil; inability to raise capital; continued losses and lack of profitability; inability to develop or obtain regulatory approval for new products; inability to protect intellectual property or infringement of others’ intellectual property; inability to obtain partners to develop and market products; termination of license agreements; competition; inability to pay any registration penalties; costs of international business operations; manufacturing problems; insufficient third-party reimbursement for products; failure to retain key personnel; product liability; inability to manage change; failure to comply with laws; failure to achieve and maintain effective internal control over financial reporting; amortization or impairment of intangibles; issues relating to Australian incorporation; potential delisting from ASX or NASDAQ; possible dilution through exercise of outstanding warrants and stock options or future stock issuances; potential restrictions from capital raises; possible influence by Pfizer; and other factors that may be described in our filings with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We do not undertake to publicly update or revise our forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied in such statements will not be realized.

For more information, please click here

Contacts:
pSivida Limited
Brian Leedman
Vice President, Investor Relations
Tel: + 61 8 9227 8327

or
Martin E. Janis & Company, Inc
US Public Relations
Beverly Jedynak
President
Tel: +1 (312) 943 1123

or
Accent Marketing Limited
European Public Relations
Eva Reuter
Tel: +49 (254) 393 0740

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

'Microcombing' creates stronger, more conductive carbon nanotube films May 5th, 2015

Testing Facility for Graphene Enhanced Composite Pipes May 5th, 2015

Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT May 5th, 2015

Silicon Storage Technology and GLOBALFOUNDRIES Announce Qualification of Automotive Grade 55nm Embedded Flash Memory Technology May 5th, 2015

Nanomedicine

Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT May 5th, 2015

Arrowhead to Report Fiscal 2015 Second Quarter Financial Results May 4th, 2015

New Nanodrug Produced in Iran from Milk Thistle May 4th, 2015

Antibacterial Ceramic Nanoparticles, Appropriate Material for Medical Devices May 3rd, 2015

Announcements

'Microcombing' creates stronger, more conductive carbon nanotube films May 5th, 2015

Testing Facility for Graphene Enhanced Composite Pipes May 5th, 2015

Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT May 5th, 2015

Silicon Storage Technology and GLOBALFOUNDRIES Announce Qualification of Automotive Grade 55nm Embedded Flash Memory Technology May 5th, 2015

Events/Classes

Oxford Instruments Asylum Research in Conjunction with the MRS OnDemand® Webinar Series Presents: “Beyond Topography: New Advances in AFM Characterization of Polymers” May 28, 2015 May 5th, 2015

Arrowhead to Report Fiscal 2015 Second Quarter Financial Results May 4th, 2015

Nanometrics to Present at the B. Riley & Co. 16th Annual Investor Conference May 2nd, 2015

No Hogwarts invitation required: Invisibility cloaks move into the real-life classroom: A new solid-state device can demonstrate the physical principles of invisibility cloaks without special equipment or magic spells April 30th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project